1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Crohn’s Disease (CD) - Epidemiology Forecast to 2030

Crohn’s Disease (CD) - Epidemiology Forecast to 2030

  • February 2021
  • 116 pages
  • ID: 6064455
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Crohn’s Disease (CD) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted CD epidemiology in the United States.

Crohn’s Disease (CD) Understanding
Crohn’s Disease (CD) is a type of Inflammatory Bowel Disease (IBD). It causes inflammation of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Inflammation caused by CD can involve different areas of the digestive tract in different people. However, this type of IBD most commonly affects the small intestine and the start of the colon. CD can cause patches of inflammation that damage multiple layers of the GI tract wall. CD can be painful and sometimes may lead to life-threatening complications.
Crohn’s is sometimes described as a chronic condition. This means that it is ongoing and life-long. The disease runs a benign course with few flare-ups in many people, while other people may have more severe disease. CD is not infectious. Crohn’s can start at any age but usually appears for the first time between the ages of 10 and 40, although there is a small peak in the number of people diagnosed over 60. Crohn’s is often categorized according to which part or parts of the gut are most affected. Sometimes it can affect more than one part of the gut. There are different types of CD, each affecting different parts of the digestive tract including ileocolitis, ileitis, gastroduodenal Crohn’s disease, jejunoileitis, and Crohn’s colitis. The causes of CD are not yet well understood but genetic, immune response and environmental factors are suspected to contribute to CD development
Crohn’s symptoms may range from mild-to-severe and vary from person to person. Patients most often present with abdominal cramps, diarrhea, delayed growth (in prepubescent patients), weight loss, fever, anemia, a right lower quadrant abdominal mass (if a complication has developed in the ileal area), or perianal fistula. In addition to having symptoms in the GI tract, some people may also experience various symptoms in other parts of the body associated with CD.
Crohn’s Disease (CD) Diagnosis
Diagnosis of CD requires a complete assessment based on clinical history, physical examination, and complementary diagnostic tests, such as assays for serological and fecal biomarkers, blood tests. The doctor may recommend additional testing to look inside the GI tract and intestine. While these tests are more invasive than others, they are often done in an outpatient setting. Intestinal endoscopies are the most accurate methods for diagnosing CD and ruling out other possible conditions, such as ulcerative colitis, diverticular disease, or cancer.
Cross-sectional imaging refers to using computerized tomography (CT) scanning or magnetic resonance imaging (MRI) to evaluate the intestinal tract and surrounding structures for the presence of inflammation or complications such as strictures, fistulae, or abnormal fluid collections. There is no single test to confirm a Crohn’s diagnosis, and CD symptoms are often similar to other conditions, including bacterial infection. The doctors may also perform a differential diagnosis to rule out other conditions that can have some of the common symptoms of CD, such as abdominal pain and diarrhea.
Epidemiology Perspective
The CD epidemiology division provides insights about the historical and current CD patient pool and forecasted trends for the United States. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
In the year 2020, the total prevalent case of CD was 825,165 cases in the United States which are expected to grow during the forecast period, i.e., 2021–2030.
The disease epidemiology covered in the report provides historical as well as forecasted CD epidemiology [segmented as Total Prevalent Cases of CD, Total Diagnosed Cases of CD, Age-specific cases of CD, Severity-specific Cases of CD, and Treated cases of CD] in the United States from 2018 to 2030.

Scope of the Report
• The CD report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The CD Report and Model provide an overview of the risk factors and global trends of CD in the United States.
• The report provides insight about the historical and forecasted patient pool of CD in the United States.
• The report helps to recognize the growth opportunities in the United States concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of CD.
• The report provides the segmentation of the CD epidemiology by total prevalent cases in the United States.
• The report provides the segmentation of the CD epidemiology by total diagnosed cases in the United States.
• The report provides the segmentation of the CD epidemiology by age-specific cases in the United States.
• The report provides the segmentation of the CD epidemiology by severity-specific cases in the United States.
• The report provides the segmentation of the CD epidemiology by treated cases in the United States.

Report Highlights

• 10-Year Forecast of CD epidemiology
• The United States Coverage
• Total Prevalent Cases of CD
• Total Diagnosed Cases of CD
• Age-Specific Cases of CD
• Severity-Specific Cases of CD
• Treated Cases of CD
KOL-Views
We interview KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the United States concerning the patient population of CD?
• What are the key findings of the CD epidemiology across the United States during the study period (2018–2030)?
• What would be the total number of patients of CD across the United States during the study period (2018–2030)?
• At what CAGR the patient population is expected to grow in the United States during the study period (2018–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of CD?

Reasons to buy
The CD Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global CD market
• Quantify patient populations in the global CD market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the gender that presents the best opportunities for CD therapeutics in the United States market covered
• Understand the magnitude of CD population by its severity
• The CD epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The CD Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
Study Period: 2018–2030
• In the United States, the total diagnosed cases of CD were 591,368 cases in the year 2020 which are expected to grow during the forecast period, i.e., 2021–2030.
• In the United States, the total age-specific cases of CD were 351,273, 166,766, 67,416, and 5,914 cases for the age group less than 18–44, 45–64, 65–84, and ?85 years, respectively in 2020.
• In the United States, the total severity-specific cases of CD were 236,547, and 354,821 cases for mild and moderate to severe cases, respectively in 2020.
• In the United States, the total treated cases of CD was 319,339 cases in the year 2020 which are expected to grow during the forecast period, i.e., 2021–2030.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Diabetic Macular Edema (DME) - Epidemiology Forecast to 2030

  • $ 3750
  • May 2021
  • 125 pages

‘Diabetic macular edema (DME)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted DME epidemiology in the 7MM, i.e., the United States, ...

  • Japan
  • United States
  • Epidemiology
  • Industry analysis
  • Elderly Population

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on